|
|
38. |
Hook E. W. 3rd, Baker-Zander S. A., Moskovitz B. L. et al. Ceftriaxone ther- |
|
|
|
apy for asymptomatic neurosyphilis. Case report and Western blot analysis of |
|
|
|
serum and cerebrospinal fluid IgG response to therapy. Sex Transm Dis 1986; |
|
|
|
13 (3 Suppl): S. 185—188. |
|
|
39. |
Hook E. W. 3rd, Behets F., Van Damme K. et al. A phase III equivalence trial |
|
|
|
of azithromycin versus benzathine penicillin for treatment of early syphilis. |
|
|
|
J Infect Dis 2010; 201 (11): 1729—1735. |
|
|
40. |
Hook E.W. 3rd, Roddy R. E., Handsfield H. H. Ceftriaxone therapy for incu- |
|
|
|
bating and early syphilis. J Infect Dis 1988; 158 (4): 881–884. [Hook-1] |
|
|
41. |
Hooshmand H., Escobar M.R., Kopf S.W. Neurosyphilis. A study of 241 pa- |
|
|
|
tients. JAMA 1972; 219: 726—9. |
|
|
42. |
Idsöe O., Guthe T., Willcox R. R. Penicillin in the treatment of syphilis. The |
|
|
|
experience of three decades. Bull WHO 1972; 47: 1—68. |
|
|
43. |
Janier M., Hegyi V., Dupin N. et al. 2014 European guideline on the manage- |
|
|
|
ment of syphilis. J Eur Acad Dermatol Venereol 2014; 28 (12): 1581—1593. |
|
|
44. |
Jinno S., Anker B., Kaur P. et al. Predictors of serological failure after treat- |
|
|
|
ment in HIV-infected patients with early syphilis in the emerging era of uni- |
|
|
|
versal antiretroviral therapy use. BMC Infect Dis 2013; 13; 605. |
|
|
45. |
Katz K. A., Klausner J. D. Azithromycin resistance in Treponema pallidum. |
|
|
|
Curr Opin Infect Dis 2008; 21 (1): 83—91. |
|
|
46. |
Löwhagen G. B., Brorson J. E. Kaijser B. Penicillin concentrations in cerebro- |
|
|
|
spinal fluid and serum after intramuscular, intravenous and oral administra- |
|
|
|
tion to syphilitic patients. Acta Derm Venereol (Stockh) 1983; 63: 53—57. |
|
|
47. |
Luger A. F., Schmidt B. L., Kaulich M. Significance of laboratory findings for |
|
|
|
the diagnosis of neurosyphilis. Int J STD & AIDS 2000; 11: 224—34. |
|
|
48. |
Lukehart S. A., Godornes C., Molini B., Sonnett P., Hopkins S., Mulcahy F. |
|
|
|
et al. Macrolide resistance in Treponema pallidum in the United States and |
|
путем |
|
Ireland. N Engl J Med 2004; 351: 154—158. |
|
49. |
Manavi K., McMillan A. The outcome of treatment of early latent syphilis |
|
|
|
половым |
|
and syphilis with undetermined duration in HIV-infected and HIV-uninfected |
|
|
patients. Int J STD AIDS 2007; 18 (12); 814—818. |
|
50. |
Marra C. M. Neurosyphilis. Current Neurology and Neuroscience Reports |
|
|
|
передаваемые |
|
2004; 4 (6): 435—440. |
|
51. |
Marra C., Maxwell C. L., Smith S. L., Lukehart S. A., Rompalo A. M. et al. |
|
|
|
|
|
Cerebrospinal fluid abnormalities in patients with syphilis: association with |
|
|
|
clinical and laboratory features. J Infect Dis 2004; 189: 369—76. |
|
|
52. |
Marra C. M., Maxwell C. L., Tantalo L. et al. Normalization of cerebrospinal |
|
Инфекции, |
|
fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin |
|
|
mycin in treatment of early syphilis. Arch Intern Med 1961; 107: 164—167. |
|
|
|
Infect Dis 2004; 38 (7): 1001—1006. |
|
|
53. |
Montgomery C. H., Knox J. M., Sciple G. W., Vander Stoep E. M. Erythro- |